🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

A Long-term Safety and Efficacy Study Evaluating CM512 in Atopic Dermatitis.

RecruitingPhase 2Ages 18 Years - anyAllKeymed Biosciences Co.Ltd
NCT07230483 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is an Open-label ,Multicenter Study to evaluate Long-Term Safety and Efficacy of CM512 in patients with Atopic Dermatitis who have completed treatment in parent CM512 Study.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Have the ability to understand the study and voluntarily sign a written informed consent form (ICF). * Subjects who have completed the week 18 evaluation in the parent study CM512-101102 or the End of Study(EOS) visit in the parent study CM512-100001. Exclusion Criteria: * Not enough washing-out period for previous therapy. * Any other condition assessed by the investigator that makes participants unsuitable for participation in this study.
💊

What it tests

  • CM512
📍

Where

1 site
Peking University People's Hospital
Beijing, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy